Clinical-grade development of research reagents and sales of products for regenerative medicine
First written in FY2017-Q1. 13 of 22 entries say "Restated". Latest entry: 2026-07-27.
2 other companies' latest entry also says "Advanced".
- 2026-07-27AdvancedBusiness Alliance
「In addition to these products, we will deploy in the Chinese market a comprehensive solution that includes our proprietary StemEdit clinical-use gene-editing service and manufacturing services for master cell banks (MCBs) and working cell banks (WCBs), which are essential to the development of cell therapy products.」
The specific scope of the collaboration was presented, covering the Chinese market deployment of clinical-use gene-editing services and MCB and WCB manufacturing services in addition to clinical-use iPS cells. - FY2026-H1RestatedAnnual report
「For clinical-use iPS cells, we provide manufactured iPS cells to pharmaceutical companies as starting materials for regenerative medicine products under a GMP-compliant manufacturing system.」
We have reaffirmed our policy of manufacturing clinical-use iPS cells in compliance with GMP and providing them as starting materials for regenerative medicine products. - FY2025-H1RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2024-Q3RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2024-Q2RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2024-Q1RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2023-Q3RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2023-Q2RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2023-Q1RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed the business of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2022-Q3RestatedAnnual report
「In August 2021, we entered into a strategic business alliance agreement with the TEXCELL Group, a French contract manufacturing organization (CMO), hereinafter referred to as TEXCELL. TEXCELL has extensive experience in contract manufacturing of GMP master cell banks in accordance with Japanese, U.S. and European guidelines. By combining our cutting-edge clinical-use iPS cells with TEXCELL's manufacturing technology, we will provide more reliable GMP-iPS Cell Master Cell Banks.」
For clinical-use iPS cells, we have reaffirmed our policy of providing GMP-iPS Cell Master Cell Banks in combination with TEXCELL's manufacturing technology. - FY2022-Q2AdvancedAnnual report
「In August 2021, we entered into a basic agreement with the TEXCELL Group, a French contract manufacturing organization (CMO), hereinafter referred to as TEXCELL. TEXCELL has extensive experience in contract manufacturing of GMP master cell banks in accordance with Japanese, U.S. and European guidelines. By combining our cutting-edge clinical-use iPS cells with TEXCELL's manufacturing technology, we will provide more reliable GMP-iPS Cell Master Cell Banks.」
The product rollout for clinical-use iPS cells advanced toward providing products that combine the manufacturing technology of GMP master cell banks following the execution of a basic agreement with TEXCELL. - FY2022-Q1RestatedAnnual report
「We provide two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
For clinical-use iPS cells, we have reaffirmed our policy of providing the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2021AdvancedAnnual report
「During the period, we launched two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals.」
In commercializing clinical-use iPS cells, we launched two services: the GMP-iPS Cell Master Cell Bank for pharmaceutical companies and Personal iPS for individuals. - FY2021-Q3RestatedAnnual report
「We had previously provided a service for producing “research-use iPS cells” for research purposes such as drug discovery. Leveraging our accumulated technologies and experience, we launched a service for producing “clinical-use iPS cells” in March 2020.」
The company has reaffirmed that it expanded its service from research-use iPS cells to clinical-use iPS cells and launched the clinical-use service in March 2020. - FY2021-Q2RestatedAnnual report
「We had previously provided a service for producing “research-use iPS cells” for research purposes such as drug discovery. Leveraging our accumulated technologies and experience, we launched a service for producing “clinical-use iPS cells” in March 2020.」
The company has reaffirmed that it expanded its service from research-use iPS cells to clinical-use iPS cells and launched the clinical-use service in March 2020. - FY2021-Q1RestatedAnnual report
「During the period under review, we newly launched a contract service for producing highly safe iPS cells for clinical use.」
The company has reaffirmed that it launched its contract service for producing clinical-use iPS cells in March 2020. - FY2020AdvancedAnnual report
「In March 2020, we launched a service for producing “clinical-use iPS cells.”」
The company expanded its service from research-use reagents and cells to clinical applications by launching a service for producing iPS cells for clinical use in March 2020. - FY2018AdvancedAnnual report
「This product consists solely of scientifically validated, highly safe ingredients. The Pharmaceuticals and Medical Devices Agency (PMDA) has confirmed that it complies with standards for biological raw materials and is suitable for use as a raw material for regenerative medicine products.」
For reagents for clinical research and regenerative medicine, progress included the launch of ReproMed iPSC Medium and ReproCryo RM, as well as confirmation of their suitability by the PMDA. - FY2017AdvancedAnnual report
「We previously began selling the cell culture medium “NutriStem” as a GMP-compliant reagent. As these reagents will be important consumables for putting regenerative medicine using iPS cells into practical use, we will promote sales going forward, primarily to companies and universities pursuing regenerative medicine.」
The company confirmed the launch of NutriStem sales as a GMP-compliant reagent and indicated a policy of promoting sales of consumables for regenerative medicine and launching additional products. - FY2017-Q3AdvancedAnnual report
「This product complies with GMP requirements. When used in combination with ReproCELL USA's culture medium “NutriStem,” it may eventually enable the creation of iPS cells for regenerative medicine applications.」
For research reagents for clinical and regenerative medicine applications, the company began selling StemRNA-NM Reprogramming Kit as a GMP-compliant product and indicated the possibility of achieving regenerative medicine grade when used in combination with NutriStem. - FY2017-Q2AdvancedAnnual report
「We are already in discussions with relevant parties, including government agencies, and have begun developing reagents that can be used for clinical applications.」
Regarding the upgrading of research reagents to clinical grade, the company has advanced discussions with relevant institutions and begun developing clinical-use reagents. - FY2017-Q1First statedAnnual report
「By upgrading existing research reagent products to clinical grade, we will increase their added value. Specifically, we have developed and begun selling products for regenerative medicine, including “bFGF Xeno-Free,” the cryopreservation solution “ReproCryo DMSO Free,” and an “RNA Reprogramming Kit” that enables the safe and efficient creation of iPS cells without using viruses.」
The company has described the development and launch of sales of specific products to increase the added value of existing research reagents for clinical applications.